Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va

Eva A Norstrøm1, Sinh Tran, Mårten Steen

  • 1Department of Laboratory Medicine, Clinical Chemistry, Lund University, the Wallenberg Laboratory, University Hospital, Malmö, SE-205 02 Malmö, Sweden.

Insights

Activated protein C inactivates factor Va (FVa) by cleaving it at specific sites. Factor Xa (FXa) inhibits cleavage at Arg-506, but Protein S counteracts this inhibition, revealing complex interactions in blood coagulation.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Activated protein C (APC) is a key regulator of blood coagulation, primarily by inactivating activated factor V (FVa).
  • APC cleaves FVa at multiple sites, with Arg-506 being the most kinetically favored, but this site is protected by factor Xa (FXa).
  • The role of Protein S in modulating FXa's protection of FVa at Arg-506 is debated.

Purpose of the Study:

  • To investigate the specific effects of FXa and Protein S on the individual cleavage sites of FVa.
  • To elucidate the mechanism by which Protein S influences FXa's interaction with FVa at the Arg-506 cleavage site.

Main Methods:

  • Utilized recombinant FVa variants (FVa:Q306/Q679 and FVa:Q506/Q679) to isolate effects on specific cleavage sites.
  • Measured FVa inactivation rates over time in the presence of active site-blocked FXa (FXa-1.5-dansyl-Glu-Gly-Arg).
  • Calculated apparent second-order rate constants to quantify inhibition and stimulation effects.

Main Results:

  • FXa significantly inhibited FVa cleavage at Arg-506 (20-fold decrease, IC50 ~2 nM).
  • FXa unexpectedly stimulated FVa cleavage at Arg-306.
  • Protein S counteracted FXa's inhibition of Arg-506 cleavage and, with FXa, showed an additive stimulatory effect on Arg-306 cleavage.

Conclusions:

  • FXa and Protein S interact with distinct sites on FVa, as Protein S does not inhibit FXa binding.
  • Protein S enhances Arg-506 cleavage of FVa not bound to FXa, leading to FXa dissociation and apparent 'annihilation' of FXa's protective effect.
  • These findings clarify the complex interplay of FXa and Protein S in regulating FVa inactivation by APC.

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...